When fear and misinformation go viral: Pharmacists' role in deterring medication misinformation during the 'infodemic' surrounding COVID-19

Jiang, 2020, Review of the clinical characteristics of coronavirus disease 2019 (COVID-19), J Gen Intern Med, 1 Cascella, 2020, Features, evaluation and treatment coronavirus (COVID-19) COVID, 2020, Severe outcomes among patients with coronavirus disease 2019 (COVID-19)—United States, february 12–march 16, 2020, MMWR Morb Mortal Wkly Rep, 69, 343, 10.15585/mmwr.mm6912e2 Verity, 2020, Estimates of the severity of coronavirus disease 2019: a model-based analysis, Lancet Infect Dis, 10.1016/S1473-3099(20)30243-7 Li, 2020, Therapeutic options for the 2019 novel coronavirus (2019-nCoV), Nat Rev Drug Discov, 19, 149, 10.1038/d41573-020-00016-0 Dong, 2020 Hoffmann, 2020, SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor, Cell, 181, 271, 10.1016/j.cell.2020.02.052 Liu, 2020, Learning from the past: possible urgent prevention and treatment options for severe acute respiratory infections caused by 2019‐nCoV, Chembiochem Yao, 2020, A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus–A possible reference for coronavirus disease‐19 treatment option, J Med Virol, 10.1002/jmv.25729 Martinez, 2020, Compounds with therapeutic potential against novel respiratory 2019 coronavirus, Antimicrob Agents Chemother, 64, 10.1128/AAC.00399-20 Hu, 2020, Risk factors associated with clinical outcomes in 323 COVID-19 patients in wuhan, China, Medrxiv Yan, 2020, Factors associated with prolonged viral shedding and impact of Lopinavir/Ritonavir treatment in patients with SARS-CoV-2 infection, Medrxiv Cai, 2020, COVID‐19 in a designated infectious diseases hospital outside hubei province, China, Allergy, 10.1111/all.14309 Cao, 2020, A trial of lopinavir–ritonavir in adults hospitalized with severe Covid-19, N Engl J Med, 10.1056/NEJMoa2001282 Deng, 2020, Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: a retrospective cohort study, J Infect, 10.1016/j.jinf.2020.03.002 Liu, 2020, Patients of COVID-19 may benefit from sustained lopinavir-combined regimen and the increase of eosinophil may predict the outcome of COVID-19 progression, Int J Infect Dis Young, 2020, Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore, J Am Med Assoc, 323, 1488, 10.1001/jama.2020.3204 Zhou, 2020, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet, 395, 1054, 10.1016/S0140-6736(20)30566-3 Choy, 2020, Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro, Antivir Res, 178, 104786, 10.1016/j.antiviral.2020.104786 Gordon, 2020, Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency, J Biol Chem Grein, 2020, Compassionate use of remdesivir for patients with severe covid-19, N Engl J Med, 10.1056/NEJMoa2007016 2020, Study to evaluate the safety and antiviral activity of remdesivir (GS-5734) in participants with moderate coronavirus disease (COVID-19) compared to standard of care treatment, ClinicalTrials.gov Identifier: NCT04292730 Cai, 2020, Experimental treatment with favipiravir for COVID-19: an open-label control study, Engineering, 10.1016/j.eng.2020.03.007 Chen, 2020, Favipiravir versus Arbidol for COVID-19: a randomized clinical trial, Medrxiv Tran, 2019, Azithromycin, a 15-membered macrolide antibiotic, inhibits influenza A (H1N1) pdm09 virus infection by interfering with virus internalization process, J Antibiot (Tokyo), 72, 759, 10.1038/s41429-019-0204-x Retallack, 2016, Zika virus cell tropism in the developing human brain and inhibition by azithromycin, Proc Natl Acad Sci U S A, 113, 14408, 10.1073/pnas.1618029113 Li, 2019, Azithromycin protects against zika virus infection by upregulating virus-induced type I and III interferon responses, Antimicrob Agents Chemother, 63, 10.1128/AAC.00394-19 Lee, 2017, Anti-inflammatory effects of adjunctive macrolide treatment in adults hospitalized with influenza: a randomized controlled trial, Antivir Res, 144, 48, 10.1016/j.antiviral.2017.05.008 Ishaqui, 2020, Assessment of efficacy of oseltamivir-azithromycin combination therapy in prevention of influenza-a (H1N1) infection complications and rapidity of symptom relief, Expert Rev Respir Med, 14, 533, 10.1080/17476348.2020.1730180 Arabi, 2019, Macrolides in critically ill patients with Middle East Respiratory Syndrome, Int J Infect Dis, 81, 184, 10.1016/j.ijid.2019.01.041 Wang, 2020, Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected pneumonia in Wuhan, China, J Am Med Assoc Devaux, 2020, New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?, Int J Antimicrob Agents, 105938, 10.1016/j.ijantimicag.2020.105938 Colson, 2020, Chloroquine and hydroxychloroquine as available weapons to fight COVID-19, Int J Antimicrob Agents, 55, 105932, 10.1016/j.ijantimicag.2020.105932 Yao, 2020, In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Clin Infect Dis, 10.1093/cid/ciaa237 Wang, 2020, Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res, 30, 269, 10.1038/s41422-020-0282-0 Gautret, 2020, Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, Int J Antimicrob Agents, 105949, 10.1016/j.ijantimicag.2020.105949 Rolain, 2007, Recycling of chloroquine and its hydroxyl analogue to face bacterial, fungal and viral infections in the 21st century, Int J Antimicrob Agents, 30, 297, 10.1016/j.ijantimicag.2007.05.015 Cortegiani, 2020, A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19, J Crit Care, S0883–9441, 30390 Chen Jun, 2020, A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19 (COVID-19), J Zhejiang Univ (Med Sci), 49 Chen, 2020, Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial, Medrxiv Mahevas, 2020, No evidence of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19 infection with oxygen requirement: results of a study using routinely collected data to emulate a target trial, medRxiv Gautret, 2020, Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: a pilot observational study, Travel Med Infect Dis, 101663, 10.1016/j.tmaid.2020.101663 Chorin, 2020, The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin, Nat Med, 10.1038/s41591-020-0888-2 Sarayani, 2020, Safety signals for QT prolongation or Torsades de Pointes associated with azithromycin with or without chloroquine or hydroxychloroquine, Res Soc Adm Pharm, 10.1016/j.sapharm.2020.04.016 Fang, 2020, Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?, Lancet Respir Med, 8, e21, 10.1016/S2213-2600(20)30116-8 Zheng, 2020, COVID-19 and the cardiovascular system, Nat Rev Cardiol, 17, 259, 10.1038/s41569-020-0360-5 Lu, 2020, Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding, Lancet, 395, 565, 10.1016/S0140-6736(20)30251-8 Liu, 2020, Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury, Sci China Life Sci, 63, 364, 10.1007/s11427-020-1643-8 American College of Cardiology European Society of Cardiology Gebistorf, 2016, Inhaled nitric oxide for acute respiratory distress syndrome (ARDS) in children and adults, Cochrane Database Syst Rev, 2016, CD002787 Åkerström, 2005, Nitric oxide inhibits the replication cycle of severe acute respiratory syndrome coronavirus, J Virol, 79, 1966, 10.1128/JVI.79.3.1966-1969.2005 Biospace Caly, 2020, The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro, Antivir Res, 178, 104787, 10.1016/j.antiviral.2020.104787 Lythgoe, 2020, Ongoing clinical trials for the management of the COVID-19 pandemic, Trends Pharmacol Sci, S0165–6147 Guerin, 2020, The consequence of COVID-19 on the global supply of medical products: why Indian generics matter for the world?, F1000Research, 9, 225, 10.12688/f1000research.23057.1 WHO, 2020 Thomas, 2018, Fake news: medicines misinformation by the media, Clin Pharmacol Ther, 104, 1059, 10.1002/cpt.1199 Rome, 2020, Drug evaluation during the covid-19 pandemic, N Engl J Med, 10.1056/NEJMp2009457 WHO, 2020 Pharmaceutcal Society of Australia, 2020 2020 Therapeutic Goods Administration, 2020 Health Do, 2020 Poudel, 2019, Pharmacist role in vaccination: evidence and challenges, Vaccine, 37, 5939, 10.1016/j.vaccine.2019.08.060 (FIP) IPF, 2020 Federation IP, 2020 Al-Quteimat, 2020, Amer AM. SARS-CoV-2 outbreak: how can pharmacists help?, Res Soc Adm Pharm, S1551–7411 Cadogan, 2020, On the frontline against COVID-19: community pharmacists' contribution during a public health crisis, Res Soc Adm Pharm, S1551–7411 Amariles, 2020, How to link patients with suspicious COVID-19 to health system from the community pharmacies? A route proposal, Res Soc Adm Pharm Sheppard, 2020, Community pharmacists and communication in the time of COVID-19: applying the health belief model, Res Soc Adm Pharm